STAU2

Across TCGA pan-cancer cohorts, STAU2 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated STAU2 data layer compared with 25 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher STAU2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated STAU2 expression acts as an unfavorable survival marker.

THYM, PAAD, and KIRP are the cancer types where STAU2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	All	0.169	0.931	<.001	33	view →
PAAD	OS	Median	All	0.110	0.640	<.001	24	view →
KIRP	OS	Median	All	0.216	0.904	<.001	15	view →
STAD	OS	Median	III,IV	0.003	0.633	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LIHC	OS	Median	All	0.257	0.690	.024	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

STAU2–THYM (OS)

Open the THYM breakdown →